Rezolute (RZLT) Shares Outstanding (Diluted Average) (2013 - 2026)
Rezolute's (RZLT) quarterly Shares Outstanding (Diluted Average) came in at $103.7 million in Q1 2026, up 48.1% year-on-year from $70.0 million in Q1 2025, and little changed quarter-over-quarter from $103.7 million in Q4 2025.
Rezolute (RZLT) Shares Outstanding (Diluted Average) (2013 - 2026) Analysis & Trends
Rezolute has disclosed Shares Outstanding (Diluted Average) across 9 years of filings, most recently posting $103.7 million for Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $103.7 million, up 48.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $103.7 million (up 48.1% YoY), and the FY2025 annual result was $76.0 million, up 47.67% from the prior year.
- Shares Outstanding (Diluted Average) came in at $103.7 million for Q1 2026 at Rezolute, roughly flat from $103.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $103.7 million in Q1 2026 to a low of $13.7 million in Q1 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $51.4 million (2023), against an average of $61.1 million.
- Across the five-year window, Shares Outstanding (Diluted Average) surged 493.54% in 2022 and grew 0.19% in 2024, its largest moves.
- Rezolute's Shares Outstanding (Diluted Average) stood at $51.0 million in 2022, then rose by 0.86% to $51.4 million in 2023, then surged by 36.05% to $69.9 million in 2024, then soared by 48.25% to $103.7 million in 2025, then increased by 0.03% to $103.7 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $103.7 million (Q1 2026), $103.7 million (Q4 2025), and $103.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 92.44 Mn |
| 10 | Rezolute | 425.23 Mn | 425.23 Mn | - | 103.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103.71 Mn |
| Dec 31, 2025 | 103.69 Mn |
| Sep 30, 2025 | 103.42 Mn |
| Jun 30, 2025 | 76.00 Mn |
| Mar 31, 2025 | 70.03 Mn |
| Dec 31, 2024 | 69.94 Mn |
| Sep 30, 2024 | 69.74 Mn |
| Jun 30, 2024 | 51.47 Mn |
| Mar 31, 2024 | 51.21 Mn |
| Dec 31, 2023 | 51.41 Mn |
| Sep 30, 2023 | 51.41 Mn |
| Jun 30, 2023 | 51.19 Mn |
| Mar 31, 2023 | 51.11 Mn |
| Dec 31, 2022 | 50.97 Mn |
| Sep 30, 2022 | 50.53 Mn |
| Jun 30, 2022 | 19.49 Mn |
| Mar 31, 2022 | 13.75 Mn |
| Dec 31, 2021 | 15.68 Mn |
| Sep 30, 2021 | 8.51 Mn |
| Jun 30, 2021 | 7.67 Mn |